Sunitinib and Capecitabine for First Line Colon Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

sunitinib and capecitabine

Sunitinib 37.5 mg po once daily Capecitabine 1000 mg po twice daily

Trial Locations (1)

20007

Lombardi Cancer Center at Georgetown University, Washington D.C.

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Georgetown University

OTHER